February 26, 2024
A key Japanese health ministry panel on February 22 gave the nod to a batch of medicines for regulatory approval, including Takeda Pharmaceutical’s susoctocog alfa for acquired hemophilia A. Susoctocog alfa is one of two new molecular entities (NMEs) by...read more